SBIR/STTR Research Award

Adjustable Injectable Intraocular Lens

Award identifier 1e5d52da2a296b4263750bdd38112b91230eceed95bab2a8a10ae8753b121958Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,476,440

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CALHOUN VISION, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Using proprietary light adjustable materials technology, Calhoun Vision's mission is to perfect vision in patients undergoing cataract and refractive surgery. The injectable, accommodating light adjustable intraocular lens system proposed to address presbyopia in the cataract patient is comprised of an injectable, gel-filled capsular lens with an adjustable, anterior capsule supported intraocular lens (AC-LAL). The AC-LAL is formulated from Calhoun Vision's proprietary light adjustable silicone material which allows for in situ post-operative refractive correction of pre-existing and induced spherical and astigmatic errors. The capsular gel lens with modulus mimicking the young human lens promotes restoration of natural accommodative ability for cataract patients. The primary goal of this Phase II proposal is to demonstrate the in vivo performance of the proposed adjustable, injectable intraocular lens system in a primate model. This will be accomplished by: (1) Optimization of UV-absorbing gel material from Phase I for mechanical and optical properties, (2) Develop the AC-LAL design based upon proprietary light adjustable materials, (3) Demonstrate the safety of the AC-LAL and gel material through biocompatibility studies, (4) Develop prototype packaging for sterile gel delivery into the eye, (5) Conduct in vitro testing to demonstrate accommodative amplitude, (6) Conduct rabbit studies to evaluate posterior capsule opacification with the proposed lens system, and (7) Demonstrate accommodation amplitude of the optimized adjustable, injectable lens system in a primate model. Presbyopia is a progressive, age-related loss of accommodation affecting 100 percent of the population which is characterized by the noticeable loss of near vision at the age of 40-45 years with complete loss of accommodation by the age of 50. Conventional treatment has been limited to reading glasses, bifocals or contact lenses. Calhoun Vision's proposed adjustable, injectable silicone intraocular lens incorporating our proprietary light adjustable lens (LAL) material technology may provide for the restoration of accommodative power with in situ post-implantation refraction correction to provide the patient with true spectacle independence for both near and distance vision.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.